Discovery of riociguat (BAY 63-2521): A potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension

ChemMedChem

Volumn 4, Issue 5, 2009, Pages 853-865

  Mittendorf, Joachim ^a   Weigand, Stefan ^a,b   Alonso Alija, Cristina ^a   Bischoff, Erwin ^a   Feurer, Achim ^a,c   Gerisch, Michael ^a   Kern, Armin ^a   Knorr, Andreas ^a   Lang, Dieter ^a   Muenter, Klaus ^a   Radtke, Martin ^a   Schirok, Hartmut ^a   Schlemmer, Karl Heinz ^a   Stahl, Elke ^a   Straub, Alexander ^a   Wunder, Frank ^a   Stasch, Johannes Peter ^a  

^a BAYER PHARMA AG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c Santhera Pharmaceuticals   (Switzerland)

Author keywords

BAY 63 2521; Pulmonary hypertension; Riociguat; sGC stimulation; Vasorelaxation

Indexed keywords

1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDINE 3 CARBONITRILE; 1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDINE 3 CARBOXAMIDE; 1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDINE 3 CARBOXIMIDAMIDE; 1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 (MORPHOLIN 4 YL)PYRIMIDINE 4,6 DIAMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 (MORPHOLIN4 YL)PYRIMIDIN 4 AMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 (PHENYDIAZENYL)PYRIMIDINE 4,6 DIAMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 METHOXY METHOXYPYRIMIDIN 4 AMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 PYRIDIN 4 YLPYRIMIDIN 4 AMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 PYRIDIN 4 YLPYRIMIDINE 4,6 DIAMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 PYRIDIN 4 YLPYRIMIDINE 4,6 DIOL; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]N 5,N 5 DIMETHYLPYRIMIDINE 4,5,6 TRIAMINE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE 4,5,6 TRIAMINE; 2 CYCLOPROPYL 3 (DIMETHYLAMINO)PROP 2 ENENITRILE; 3 (4,6 DICHLORO 5 PYRIDIN 4 YLPYRIMIDIN 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDINE; 3 (DIMETHYLAMINO) 2 (MORPHOLIN 4 YL)PROP 2 ENENITRILE; 3 [4 AMINO 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 5 YL] 1,3 OXAZOLIDIN 2 ONE; 4 AMINO 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 5 OL; 4 AMINO 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 5 YL METHONESULFONATE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 4 AMINE; 5 ETHYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE 4,6 DIAMINE; BAY 63 2521; ETHYL 1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDINE 3 CARBOXYLIC ACID; ETHYL 5 AMINO 1 (2 FLUOROBENZYL) 1H PYRAZOLE 3 CARBOXYLIC ACID; GUANYLATE CYCLASE ACTIVATOR; N [4,6 DIAMINO 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 5 YL] N METHYLPROPANE 2 SULFONAMIDE; N [4,6 DIAMINO 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 5 YL]PROPANE 2 SULFONAMIDE; RIOCIGUAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; 3 (4 AMINO 5 CYCLOPROPYLPYRIMIDINE 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO(3,4 B)PYRIDINE; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; BAY 63-2521; CELL RECEPTOR; GUANYLATE CYCLASE; MORPHOLINE DERIVATIVE; NITRIC OXIDE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SOLUBLE GUANYLYL CYCLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EXERCISE; FEMALE; IC 50; LUNG HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG POTENTIATION; METABOLISM; ORAL DRUG ADMINISTRATION; RABBIT; SIGNAL TRANSDUCTION; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; DOGS; DRUG DISCOVERY; FEMALE; GUANYLATE CYCLASE; HYPERTENSION, PULMONARY; MORPHOLINES; NITRIC OXIDE; PYRAZOLES; PYRIDINES; PYRIMIDINES; RABBITS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67651094166     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900014     Document Type: Article

References (65)

1. a) O. V. Evgenov, P. Pacher, P. M. Schmidt, G. Hasko, H. H. Schmidt, J.-P. Stasch, Nat. Rev. Drug Discovery 2006, 5, 755-768;
2. b) M. Hoenicka, C. Schmid, Cardiovasc. Hematol. Agents 2008, 6, 287-301;
3. c) J.-P. Stasch, A. J. Hobbs in Handbook of Experimental Pharmacology, Vol.191 (Eds.: F. Hofmann, H. H. Schmidt, J.-P. Stasch), Springer, Berlin, 2009, pp. 277-308.
4. a) S. P. Gaine, L. J. Rubin, Lancet 1998, 352, 719-725;
5. b) V. V. McLaughlin, M. D. McGoon, Circulation 2006, 114, 1417-1431.
6. M. M. Hoeper, L. J. Rubin, Am. J. Respir. Crit. Care. Med. 2006, 173, 499-505.
7. a) A. Giaid, D. Saleh, N. Engl. J. Med. 1995, 333, 214-221;
8. b) H. W. Faber, J. Loscalzo, N. Engl. J. Med. 2004, 351, 1655-1665;
9. c) R. F. Machado, M. L. Nerkar, R. A. Dweik, J. Hammel, A. Janocha, J. Pyle, D. Laskowski, C. Jennings, A. C. Arroliga, S. C. Erzurum, Free Radical Biol. Med. 2004, 37, 1010-1017.
10. H. A. Ghofrani, I. H. Osterloh, F. Grimminger, Nat. Rev. Drug Discovery 2006, 5, 689-702.
11. H. A. Ghofrani, F. Grimminger, in Handbook of Experimental Pharmacology, Vol.191 (Eds.: F. Hofmann, H. H. Schmidt, J.-P. Stasch), Springer, Berlin, 2009, pp. 469-483.
12. A. Chockalingam, G. Gnanavelu, S. Venkatesan, S. Elangovan, V. Jagannathan, T. Subramaniam, R. Alagesan, S. Dorairajan, Int. J. Cardiol. 2005, 99, 91-95.
13. a) F. N. Ko, C. C. Wu, S. C. Kuo, F. Y. Lee, C. M. Teng, Blood 1994, 84, 4226-4233;
14. b) C. C. Wu, F. N. Ko, S. C. Kuo, F. Y. Lee, C. M. Teng, Br. J. Pharmacol. 1995, 116, 1973-1978;
15. c) A. Friebe, G. Schultz, D. Koesling, EMBO J. 1996, 15, 6863-6868;
16. d) A. Mülsch, J. Bauersachs, A. Schäfer, J.-P. Stasch, R. Kast, R. Busse, Br. J. Pharmacol. 1997, 120, 681-689;
17. e) M. Hoenicka, E.-M. Becker, H. Apeler, T. Sirichoke, H. Schrçder, R. Gerzer, J.-P. Stasch, J. Mol. Med. 1999, 77, 14-23.
18. a) A. Straub, J.-P. Stasch, C. Alonso-Alija, J. Benet-Buchholz, B. Ducke, A. Feurer, C. Fuerstner, Bioorg. Med. Chem. Lett. 2001, 11, 781-784;
19. b) J.-P. Stasch, E. M. Becker, C. Alonso-Alija, H. Apeler, K. Dembowsky, A. Feurer, R. Gerzer, T. Minuth, E. Perzborn, U. Pleiss, H. Schroeder, W. Schroeder, E. Stahl, W. Steinke, A. Straub, M. Schramm, Nature 2001, 410, 212-215;
20. c) J.-P. Stasch, C. Alonso-Alija, H. Apeler, K. Dembowsky, A. Feurer, T. Minuth, E. Perzborn, M. Schramm, A. Straub, Br. J. Pharmacol. 2002, 135, 333-343;
21. d) J.-P. Stasch, E. Perzborn, E. Stahl, M. Schramm, Br. J. Pharmacol. 2002, 135, 344-355;
22. e) A. Straub, J. Benet-Buchholz, R. Froede, A. Kern, C. Kohlsdorfer, P. Schmitt, T. Schwarz, H.-M. Siefert, J.-P. Stasch, Bioorg. Med. Chem. 2002, 10, 1711-1717.
23. a) J. A. Winger, E. R. Derbyshire, M. A. Marletta, J. Biol. Chem. 2007, 282, 897-907;
24. b) M. Lamothe, F. J. Chang, N. Balashova, R. Shirokov, A. Beuve, Biochemistry 2004, 43, 3039-3048;
25. c) F. J. Chang, S. Lemme, Q. Sun, R. K. Sunahara, A. Beuve, J. Biol. Chem. 2005, 280, 11513-11519;
26. d) S. Yazawa, H. Tsuchiya, H. Hori, R. Makino, J. Biol. Chem. 2006, 281, 21763-21770.
27. a) R. Dumitrascu, N. Weissmann, H. A. Ghofrani, E. Dony, K. Beuerlein, H. Schmidt, J.-P. Stasch, M. J. Gnoth, W. Seeger, F. Grimminger, R. T. Schermuly, Circulation 2006, 113, 286-295;
28. b) O. V. Evgenov, F. Ichinose, N. V. Evgenov, M. J. Gnoth, G. E. Falkowski, Y. Chang, K. D. Bloch, W. M. Zapol, Circulation 2004, 110, 2253-2259;
29. c) G. Boerrigter, J. C. Burnett, Cardiovascular Drug Reviews, 2007, 25, 30-45.
30. F. Wunder, J.-P. Stasch, J. Huetter, C. Alonso-Alija, J. Hueser, E. Lohrmann, Anal. Biochem. 2005, 339, 104-112.
31. C. Alonso-Alija, E. Bischoff, K. Muenter, J.-P. Stasch, E. Stahl, S. Weigand, A. Feurer, Int. Pat. Appl. WO 03/095451 A1, 2003.
32. R. T. Schermuly, J.-P. Stasch, S. S. Pullamsetti, R. Middendorff, D. Müller, K.-D. Schlüter, A. Dingendorf, S. Hackemack, E. Kolosionek, C. Kaulen, R. Dumitrascu, N. Weissmann, J. Mittendorf, W. Klepetko, W. Seeger, H. A. Ghofrani, and F. Grimminger, Eur. Respir. J. 2008, 32, 881-891.
33. R. Frey, W. Mueck, S. Unger, U. Artmeier-Brandt, G. Weimann, G. Wensing, J. Clin. Pharmacol. 2008, 48, 926-934.
34. F. Grimminger, G. Weimann, R. Frey, R. Voswinckel, M. Thamm, D. Bölkow, N. Weissmann, W. Mück, S. Unger, G. Wensing, R. T. Schermuly, H. A. Ghofrani, Eur. Respir. J. 2009, 33, DOI: 10.1183/09031936.00039808.
35. H. A. Ghofrani, data presented at the Annual Congress of the European Respiratory Society (ERS) in Berlin (Germany), October 5, 2008.
36. Prepared analogously to: W. Borsche, R. Manteuffel, Justus Liebigs Ann. Chem. 1934, 512, 97-111;
37. See also: P. Rzepecki, H. Gallmeier, N. Geib, K. Cernovska, B. Ko̧nig, T. Schrader, J. Org. Chem. 2004, 69, 5168-5178.
38. J. L. Kelley, R. G. Davis, E. W. McLean, R. C. Glen, F. E. Soroko, B. R. Cooper, J. Med. Chem. 1995, 38, 3884-3888.
39. G. M. Shutske, J. E. Roehr, J. Heterocycl. Chem. 1997, 34, 789-795.
40. T. Sakamoto, Y. Kondo, H. Yamanaka, Synthesis 1984, 252-254.
41. a) For a review, see: A. R. Muci, S. L. Buchwald in Topics in Current Chemistry, Vol.219 (Ed.: N. Miyaura), Springer, Berlin, Heidelberg, 2002, pp. 131-209;
42. b) For a more recent protocol, see: M. D. Charles, P. Schultz, S. L. Buchwald, Org. Lett. 2005, 7, 3965-3968.
43. G. B. Rosso, Synlett 2006, 809-810.
44. M. K. Nayak, A. K. Chakraborti, Tetrahedron Lett. 1997, 38, 8749-8752.
45. M. P. Sammes, C. W. F. Leung, A. R. Katritzky, J. Chem. Soc. Perkin Trans. 1 1981, 2835-2839.
46. V. J. Ram, M. Nath, Indian J. Chem. Sect. B 1997, 36, 394-398.
47. a) R. W. J. Carney, J. Wojtkunski, Org. Prep. Proced. Int. 1973, 5, 25-29;
48. b) Q. Li, D. T. W. Chu, A. Claiborne, C. S. Cooper, C. M. Lee, K. Raye, K. B. Berst, P. Donner, W. Wang, L. Hasvold, A. Fung, Z. Ma, M. Tufano, R. Flamm, L. L. Shen, J. Baranowski, A. Nilius, J. Alder, J. Meulbroek, K. Marsh, D. Crowell, Y. Hui, L. Seif, L. M. Melcher, R. Henry, S. Spanton, R. Faghih, L. L. Klein, S. K. Tanaka, J. J. Plattner, J. Med. Chem. 1996, 39, 3070-3088.
49. a) D. A. Claremon, B. T. Phillips, Tetrahedron Lett. 1988, 29, 2155-2158;
50. b) H. Nemoto, Y. Kubota, Y. Yamamoto, J. Org. Chem. 1990, 55, 4515-4516.
51. H. Zhao, A. Thurkauf, J. Braun, R. Brodbeck, A. Kieltyka, Bioorg. Med. Chem. Lett. 2000, 10, 2119-2122.
52. J. C. Dunham, A. D. Richardson, R. E. Sammelson, Synthesis 2006, 680-686.
53. H. Gold, O. Bayer, Chem. Ber. 1961, 94, 2594-2596.
54. a) H. Plieninger, R. El-Berins, H. Mah, Chem. Ber. 1971, 104, 3983-3985;
55. b) L. de Vries, J. Am. Chem. Soc. 1978, 100, 926-933.
56. A. Hantzsch, K. J. Thompson, Ber. Dtsch. Chem. Ges. 1905, 38, 2266-2276.
57. a) J. Baddiley, B. Lythgoe, A. R. Todd, J. Chem. Soc., 1943, 386-387;
58. b) L. F. Cavalieri, J. F. Tinker, A. Bendich, J. Am. Chem. Soc. 1949, 71, 533-536;
59. c) R. M. Evans, P. G. Jones, P. J. Palmer, F. F. Stephens, J. Chem. Soc., 1956 4106-4113;
60. d) S. Narita, T. Kitagawa, E. Hirai, Chem. Pharm. Bull. 1985, 33, 4928-4934;
61. e) F. Seyama, K. Akahori, Y. Sakata, S. Misumi, M. Aida, C. Nagata, J. Am. Chem. Soc. 1988, 110, 2192-2201;
62. f) B. Singh, G. Y. Lesher, Synthesis 1991, 211-213.
63. D. J. Fenick, D. E. Falvey, J. Org. Chem. 1994, 59, 4791-4799.
64. N. Kreutzkamp, H.-Y. Oei, Chem. Ber. 1968, 101, 2459-2463.
65. C. A. Lipinski, J. L. LaMattina, P. J. Oates, J. Med. Chem. 1986, 29, 2154-2163.